Characterization of a 2,4-Dinitrochlorobenzene-Induced Chronic Dermatitis Model in Rats

被引：45

作者：

Fujii, Y. ^{[1
]}

Takeuchi, H. ^{[1
]}

Sakuma, S. ^{[1
]}

Sengoku, T. ^{[1
]}

Takakura, S. ^{[1
]}

机构：

[1] Astellas Pharma Inc, Drug Discovery Res, Appl Pharmacol Res Labs, Osaka, Japan

来源：

SKIN PHARMACOLOGY AND PHYSIOLOGY | 2009年 / 22卷 / 05期

关键词：

Atopic dermatitis; Allergic contact dermatitis; Tacrolimus; BROWN-NORWAY RAT; ATOPIC-DERMATITIS; TACROLIMUS OINTMENT; NC/NGA MICE; CONTACT HYPERSENSITIVITY; SCRATCHING BEHAVIOR; TOPICAL APPLICATION; CYCLOSPORINE-A; SKIN DISEASES; PATHOGENESIS;

D O I：

10.1159/000235551

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100227 [皮肤病学];

摘要：

Although many mouse models of atopic dermatitis have been reported, few rat models have been studied. In this study, a rat chronic allergic dermatitis model was developed and evaluated as a pharmacological model of atopic dermatitis. Prominent ear thickening and scratching were induced after the application of 2,4-dinitrochlorobenzene to the right ear of Brown Norway rats 3 times per week for 3 weeks. Histopathologically, infiltration of T cells in the ear was observed on day 7, and eosinophils and mast cells were found in addition to T cells on day 21. The expression of interferon-gamma and interleukin-4 was increased on day 7 when compared with normal rats. However, interferon-gamma expression had disappeared by day 21. Tacrolimus ointment applied after ear tissue thickening fully developed, suppressed chronic dermatitis in a dose-dependent manner. This model has some symptomatic and histopathological similarities to atopic dermatitis and might be useful in pharmacological studies. Copyright (C) 2009 S. Karger AG, Basel

引用

页码：240 / 247

页数：8

共 42 条

[1]

Characterization of the skin penetration of a hydrocarbon-based weapons maintenance oil [J].

Arfsten, Darryl P. ;

Garrett, Carol M. ;

Jederberg, Warren W. ;

Wilfong, Erin R. ;

McDougal, James N. .

JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE, 2006, 3 (09) :457-464

[2]

Pathophysiologic mechanisms in atopic dermatitis [J].

Boguniewicz, M ;

Leung, DYM .

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2001, 20 (04) :217-225

[3]

Dermal penetration and metabolism of five glycidyl ethers in human, rat and mouse skin [J].

Boogaard, PJ ;

Denneman, MA ;

Van Sittert, NJ .

XENOBIOTICA, 2000, 30 (05) :469-483

[4]

ATOPIC-DERMATITIS - RECENT TRENDS IN PATHOGENESIS AND THERAPY [J].

COOPER, KD .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (01) :128-137

[5]

What's new in atopic dermatitis? [J].

Eedy, DJ .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 145 (03) :380-384

[6]

PATHOGENESIS AND MANAGEMENT OF ATOPIC-DERMATITIS [J].

FRIEDMANN, PS ;

TAN, BB ;

MUSABA, E ;

STRICKLAND, I .

CLINICAL AND EXPERIMENTAL ALLERGY, 1995, 25 (09) :799-806

[7]

Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity [J].

Geba, GP ;

Ptak, W ;

Askenase, PW .

IMMUNOLOGY, 2001, 104 (02) :235-242

[8]

GROEN H, 1993, TRANSPL P, V25, P2782

[9]

SELECTION OF A HUMAN T-HELPER TYPE-1 LIKE T-CELL SUBSET BY MYCOBACTERIA [J].

HAANEN, JBAG ;

MALEFIJT, RD ;

RES, PCM ;

KRAAKMAN, EM ;

OTTENHOFF, THM ;

DEVRIES, RRP ;

SPITS, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (03) :583-592

[10]

Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice [J].

Hiroi, J ;

Sengoku, T ;

Morita, K ;

Kishi, S ;

Sato, S ;

Ogawa, T ;

Tsudzuki, M ;

Matsuda, H ;

Wada, A ;

Esaki, K .

JAPANESE JOURNAL OF PHARMACOLOGY, 1998, 76 (02) :175-183

← 1 2 3 4 5 →